Zojwalla, Naseem J.
Merck & Co., Inc., Rahway, NJ, USA (United States)
6 papers on CoChat
Most cited papers
- Verified
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors
Cited by 1,332
- Verified
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature
Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment
Cited by 709
- Verified
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 393
- Verified
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 305
- Verified
Phase II Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2020) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 42
- Verified
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Wang, K., Wallace, E., Josey, J. A., et al. (2016) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free